EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Long-Term Therapy with Eculizumab Biosimilar in Patients with Atypical Haemolytic Uraemic Syndrome: Outcomes of a Prospective Observational Study

Oleg Kotenko, Natalia Kozlovskaya, Khadizha Emirova, Alexander Muzurov, Sergey Moiseev, Irina Konakova, Aleksey Shavkin, Tamara Makarova, Maria Gazizulina, Vladimir Vinogradov, Ekaterina Ivanova, Kseniya Demyanova und 7 weitere

Nephron · 12.06.2026 · 1-10

DOI: 10.1159/000552914 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephron, online erschienen am 12.06.2026. Verfasst von Oleg Kotenko und 18 weiteren Autor:innen. Beteiligte Einrichtung: Moscow City Nephrology and Transplanted Kidney Pathology Center, City Clinical Hospital No. 52, Moscow, Russian Federation. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The objective of a multicentre, prospective, observational study of an eculizumab biosimilar (Elizaria®) was to analyse the efficacy and safety of long-term complement inhibitor therapy in patients with atypical haemolytic uraemic syndrome (aHUS). Materials and Methods: The study included 50 patients aged 1–55 years, with 42% of them under the age of 18. The patients received the eculizumab biosimilar in routine clinical practice within 56 weeks; 19 patients (38%) had been treated with eculizumab prior to enrolment, whereas 31 patients (62%) were naive to complement inhibitors.

Results

By the end of the study, an increase in platelet count of 39.48 ± 21.7 × 109/L and 33.61 ± 24.06 × 109/L was reported in treatment-naive and treatment-experienced patients, respectively. By the end of the study, 96% of treatment-experienced patients and 100% of treatment-naive patients had normal platelet counts. The mean LDH activity did not change significantly, with levels of 253.84 ± 122.22 U/L registered at screening and 245.24 ± 93.52 U/L at the end of the study. In total, 39 patients (77.6%) at week 21 and 40 patients (80%) at week 52 had no thrombotic microangiopathy (TMA) events. During the study, the proportion of patients with a complete TMA response increased significantly, rising to 8% (p = 0.046). The proportion of patients with an estimated glomerular filtration rate improvement of 15 mL/min/1.73 m2 and more at week 52 was 12%. During the safety assessment, 63 adverse events not related to the investigational medicinal product were reported.

Conclusion

Long-term complement inhibitor therapy with the eculizumab biosimilar in patients with aHUS has demonstrated a stable effect, a favourable safety profile, and low immunogenicity.

Schlagwörter

Stichwörter der Autor:innen

Atypical haemolytic uraemic syndromeEculizumabEfficacyEstimated glomerular filtration ratePlatelet countSafetyThrombotic microangiopathy

Autor:innen und Institutionen

  • Moscow City Nephrology and Transplanted Kidney Pathology Center, City Clinical Hospital No. 52, Moscow, Russian Federation.
  • Department of General Therapy, Pirogov Russian National Research Medical University, Moscow, Russian Federation.
  • Nephrology Center for Pregnant Women with Kidney Disease, Eramishantsev City Clinical Hospital, Moscow, Russian Federation.
  • Department of Internal Medicine, Patrice Lumumba Peoples' Friendship University of Russia, Moscow, Russian Federation.
  • Center for Gravitational Blood Surgery and Hemodialysis, St. Vladimir Children's City Clinical Hospital, Moscow, Russian Federation.
  • Department of Pediatrics, Russian University of Medicine, Moscow, Russian Federation.

Zitieren

APA

Kotenko, O., Kozlovskaya, N., Emirova, K., Muzurov, A., Moiseev, S., Konakova, I., Shavkin, A., Makarova, T., Gazizulina, M., Vinogradov, V., Ivanova, E., Demyanova, K., Korotchaeva, Y., Proshina, T., Melnikova, Y., Рoladova, L., Mazur, Y., Markova, O., & Borozinets, A. (2026). Long-Term Therapy with Eculizumab Biosimilar in Patients with Atypical Haemolytic Uraemic Syndrome: Outcomes of a Prospective Observational Study. Nephron, 1-10. https://doi.org/10.1159/000552914

Vancouver

Kotenko O, Kozlovskaya N, Emirova K, Muzurov A, Moiseev S, Konakova I, et al. Long-Term Therapy with Eculizumab Biosimilar in Patients with Atypical Haemolytic Uraemic Syndrome: Outcomes of a Prospective Observational Study. Nephron. 2026:1-10. doi:10.1159/000552914

BibTeX
@article{Kotenko2026,
  author = {Kotenko, Oleg and Kozlovskaya, Natalia and Emirova, Khadizha and Muzurov, Alexander and Moiseev, Sergey and Konakova, Irina and Shavkin, Aleksey and Makarova, Tamara and Gazizulina, Maria and Vinogradov, Vladimir and Ivanova, Ekaterina and Demyanova, Kseniya and Korotchaeva, Yulia and Proshina, Tatiana and Melnikova, Yulia and Рoladova, Lyudmila and Mazur, Yulia and Markova, Oksana and Borozinets, Anton},
  title = {Long-Term Therapy with Eculizumab Biosimilar in Patients with Atypical Haemolytic Uraemic Syndrome: Outcomes of a Prospective Observational Study},
  journal = {Nephron},
  year = {2026},
  pages = {1--10},
  doi = {10.1159/000552914}
}
Kostenlos starten →